CSIMarket
Company Name or Ticker Symbol
Search for other Categories
 
 
 


Atara Biotherapeutics, Inc.  (ATRA)
Other Ticker:  
 
    Sector  Healthcare    Industry Biotechnology & Drugs
 
   Industry Biotechnology & Drugs
   Sector  Healthcare
 

ATRA's Income from Cont. Operations Growth by Quarter and Year

Atara Biotherapeutics,'s Income from Cont. Operations results by quarter and year




ATRA Income from Cont. Operations (in millions $) FY 2018 FY 2017 FY 2016 FY 2015
IV Quarter December - -35.31 -18.24 -21.25
III Quarter September - -31.10 -25.37 -11.87
II Quarter June -50.88 -27.43 -18.88 -14.95
I Quarter March -41.44 -25.65 -16.56 -9.16
FY   -92.32 -119.49 -79.05 -57.23



ATRA Income from Cont. Operations second quarter 2018 Y/Y Growth Comment
Atara Biotherapeutics, Inc. in the second quarter recorded loss from continued operations of $ -50.88 millions.

According to the results reported in the second quarter, Atara Biotherapeutics, Inc. achieved the best Income from Cont. Operations growth in Biotechnology & Drugs industry. While Atara Biotherapeutics, Inc.' s Income from Cont. Operations no change of % ranks overall at the positon no. in the second quarter.




ATRA Income from Cont. Operations ( Y/Y Growth %) 2018
2017 2016 2015
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Atara Biotherapeutics,'s second quarter 2018 Income from Cont. Operations $ -50.88 millions ATRA's Income Statement
Atara Biotherapeutics,'s second quarter 2017 Income from Cont. Operations $ -27.43 millions Quarterly ATRA's Income Statement
New: More ATRA's historic Income from Cont. Operations Growth >>


ATRA Income from Cont. Operations (Quarter on Quarter Growth %)

2018
2017 2016 2015
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Income from Cont. Operations second quarter 2018 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Income from Cont. Operations by Quarter for the Fiscal Years 2015, 2016, 2017, 2018
You need to upgrade your Flash Player

Atara Biotherapeutics,'s Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ATRA's II. Quarter Q/Q Income from Cont. Operations Comment
Current loss from continued operations of -50.88 millions by Atara Biotherapeutics, Inc. come out even more unfavourable compare to the loss from continued operations -41.44 millions a quarter before.

Within Biotechnology & Drugs industry Atara Biotherapeutics, Inc. achieved highest sequential Income from Cont. Operations growth. While Atara Biotherapeutics,'s Income from Cont. Operations growth quarter on quarter, overall rank is .


Atara Biotherapeutics,'s 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Jun 30 2018)
12 Months Ending
(Mar 31 2018)
12 Months Ending
(Dec 31 2017)
12 Months Ending
(Sep 30 2017)
12 Months Ending
(Jun 30 2017)
Cumulative Income from Cont. Operations 12 Months Ending $ -158.74 $ -135.28 $ -119.49 $ -102.41 $ -96.69
Y / Y Income from Cont. Operations Growth (TTM) - - - - -
Year on Year Income from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential Income from Cont. Operations Change (TTM) - - - - -
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # # # # #




Cumulative Income from Cont. Operations growth Comment
Atara Biotherapeutics, Inc.' has realized cumulative trailing twelve months loss from continued operations of $ -159 millions in the Jun 30 2018 period.
The business is getting worse as the cumulative loss from continued operations is getting bigger from $ -135.28 millions in TTM ending quarter Mar 31 2018 and $ -41.44 millions from the TTM period ending Jun 30 2017 Samuel O. Thompson wrote.

Atara Biotherapeutics, Inc. achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #


You need to upgrade your Flash Player




Other Income from Cont. Operations Growth
Biotechnology & Drugs Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
ATRA's Income from Cont. Operations Growth Ratio versus Biotechnology & Drugs Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for ATRA's Competitors
Income from Cont. Operations Growth for Atara Biotherapeutics,'s Suppliers
Income from Cont. Operations Growth for ATRA's Customers

You may also want to know
ATRA's Annual Growth Rates ATRA's Profitability Ratios ATRA's Asset Turnover Ratio ATRA's Dividend Growth
ATRA's Roe ATRA's Valuation Ratios ATRA's Financial Strength Ratios ATRA's Dividend Payout Ratio
ATRA's Roa ATRA's Inventory Turnover Ratio ATRA's Growth Rates ATRA's Dividend Comparisons



Companies with similar Income from Cont. Operations no change for the quarter ending Jun 30 2018 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Jun 30 2018
Abiomed Inc  140.99 %$ 140.986 millions
Prestige Brands Holdings, Inc.  139.72 %$ 139.717 millions
National Healthcare Corp  111.70 %$ 111.704 millions
U S Physical Therapy Inc  107.14 %$ 107.136 millions
Lemaitre Vascular Inc  88.92 %$ 88.925 millions
Ensign Group, Inc  80.34 %$ 80.339 millions
Supernus Pharmaceuticals Inc  76.97 %$ 76.975 millions
Inogen Inc  75.22 %$ 75.222 millions
Medpace Holdings, Inc.  73.43 %$ 73.432 millions
Amyris, Inc.  72.10 %$ 72.097 millions
Imprimis Pharmaceuticals, Inc.  69.95 %$ 69.946 millions
Cambrex Corp  62.60 %$ 62.601 millions
Innoviva, Inc.  61.09 %$ 61.088 millions
Zynex Inc  60.77 %$ 60.771 millions
Addus Homecare Corp  59.15 %$ 59.148 millions
Jrsis Health Care Corp  56.50 %$ 56.504 millions
Align Technology Inc  53.38 %$ 53.377 millions
Edwards Lifesciences Corp  51.91 %$ 51.908 millions
Davita Inc.  47.66 %$ 47.656 millions
Lhc Group, Inc  45.54 %$ 45.537 millions
West Pharmaceutical Services Inc  44.59 %$ 44.588 millions
Corcept Therapeutics Inc  43.88 %$ 43.876 millions


Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

KMPH's Profile

Stock Price

KMPH's Financials

Business Description

Fundamentals

Charts & Quotes

KMPH's News

Suppliers

KMPH's Competitors

Customers & Markets

Economic Indicators

KMPH's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Expectations

Management Effectivness

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us



CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2018 CSIMarket, Inc. All rights reserved. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)
Intraday Data provided by Barchart and subject to terms of use. To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Stock Price, historical and current end-of-day data provided by eoddata. Intraday data delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Barchart and Eoddata. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071